FRIDAY, SEPTEMBER 30, 2016

Advaxis nominated for Novartis award

Advaxis, Inc., a developer of next generation immunotherpies for cancer and infectious diseases, recently announced that his been nominated for an award by Novartis Vaccines and Diagnostics.

The company was nominated for the Best Early-Stage Vaccine Biotech as part of Novartis's Vaccine Industry Excellence Awards. The awards were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the last year.

Novartis chooses the companies based on their capacity to move their business from early stage to mature. They are also examined for their quality and the diversity of their pipeline clinical advancements, meaningful partnerships and their success in securing funds for additional growth.

The award winner will be announced in mid-April at the 6th annual ViE Awards Ceremony & Gala Dinner held in Washington, DC. The awards are timed to be in conjunction with the 13th Annual World Vaccines and Expo Conference in the capital.

"We are delighted to be nominated in two consecutive years for a ViE award," Thomas A. Moore, Advaxis Chairman and CEO, said. "In 2012, we made tremendous progress advancing our lead program in the clinic and achieved proof-of-concept of ADXS-HPV in the indication of cervical cancer.

"Our mission is to continue to set the foundation to become the industry leader in immunotherapy drug development and HPV-associated cancer research. The nomination for Best Early-Stage Vaccine Biotech validates the Company's research and clinical development over the past year."